Intracerebral hemorrhage

Viz.ai and NICO Corporation Announce Collaboration to Improve Outcomes in Patients with Intracerebral Hemorrhage

Retrieved on: 
星期三, 四月 17, 2024
Health, Technology, Neurology, Surgery, Health Technology, Software, Artificial Intelligence, ENRICH, Brain, Stroke, Bleeding, Radiology, ICH, Hospital, AI, NICO, MD, Neurosurgery, NCCT, Disease, Patient, MIPS, Intracerebral hemorrhage, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with NICO Corporation (NICO), a leader in modern minimally-invasive interventional technologies for neurosurgery, to improve the lives of patients with intracerebral hemorrhages.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with NICO Corporation (NICO), a leader in modern minimally-invasive interventional technologies for neurosurgery, to improve the lives of patients with intracerebral hemorrhages.
  • Intracerebral hemorrhage (ICH) is caused by bleeding within the brain tissue itself and is a life-threatening type of stroke.
  • ICH accounts for up to 15% of all strokes and has high morbidity and mortality rates, demanding swift response.
  • “Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH): Study Protocol for a Multi-Centered Two-Arm Randomized Adaptive Trial.” Frontiers in Neurology, vol.

EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING

Retrieved on: 
星期五, 四月 12, 2024
Amyloid, Angioedema, Brain, Anticoagulant, Neuroimaging, Patient, Vascular malformation, Lecanemab, Siderosis, Dementia, Cell, Seizure, ARIA, Risk, Aspirin, Focal neurologic signs, Nausea, Cerebral edema, Dizziness, Paracetamol, Arthralgia, Cerebral amyloid angiopathy, Effectiveness, Genetic testing, Intraparenchymal hemorrhage, Observation, Confusion, Alzheimer's disease, Intracerebral hemorrhage, Status epilepticus, Vomiting, Incidence, Aneurysm, Anaphylaxis, Headache, Hypersensitivity, Hypertension, MRI, Magnetic resonance imaging, Chills, Neuron, Bronchospasm, Fatal, Hypotension, Tissue plasminogen activator, Edema, Fever, Excipient, Pharmaceutical industry

Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

Key Points: 
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • There is no experience in patients who continued dosing through symptomatic ARIA-E or through asymptomatic, but radiographically severe, ARIA-E.
  • There is limited experience in patients who continued dosing through asymptomatic but radiographically mild to moderate ARIA-E.

China Medical University Hospital (CMUH) Developing iDREAM to Detect Sleep Apnea at Home

Retrieved on: 
星期六, 三月 30, 2024
Quanta, Cloud, Diagnosis, Sleep, UPPP, Sleep apnea, Certification, Sudden death, Intracerebral hemorrhage, Otorhinolaryngology, Patient, Heart rate, Stroke, Research, AI, Record, Snoring, Society, OSAS, Hospital, Electroencephalography, Automation, Hypertension, Respiratory system, Family, Food, Physician, ECG, Apnea, Pharmaceutical industry

TAICHUNG, March 30, 2024 /PRNewswire/ -- Snoring can be an alarming sign of obstructive sleep apnea syndrome (OSAS). Studies showed that 50% of individuals who snore may experience sleep apnea, which can lead to life-threatening conditions such as heart disease, hypertension, intracerebral hemorrhage, stroke, and even sudden death during night-time in severe cases. Sleep Medicine Center at China Medical University Hospital (CMUH, Taiwan) has introduced iDREAM (Intelligent Detection of Respiratory Events through Automated Monitoring), incorporating Quanta's QOCA Portable ECG Monitoring Device, as a simple solution to efficiently detect symptoms of apnea patients during their sleep at home. More than 100 patients have been in clinical trials of iDREAM. With this AI-powered ECG analysis, CMUH's physicians are able to identify obstructive sleep apnea syndrome (OSAS) more accurately and to reduce the time spent for diagnosis and treatment.

Key Points: 
  • Sleep Medicine Center at China Medical University Hospital (CMUH, Taiwan) has introduced iDREAM (Intelligent Detection of Respiratory Events through Automated Monitoring), incorporating Quanta's QOCA Portable ECG Monitoring Device, as a simple solution to efficiently detect symptoms of apnea patients during their sleep at home.
  • With this AI-powered ECG analysis, CMUH's physicians are able to identify obstructive sleep apnea syndrome (OSAS) more accurately and to reduce the time spent for diagnosis and treatment.
  • iDREAM , the home-based sleep detection system, detects ECG change from OSAS episodes and determines severity using its deep learning methodology.
  • It demonstrates 92.7% and 93.2% accuracy for sleep apnea and wake-up events (interruption of sleep from apnea), and 95.8% accuracy for defining severe OSAS (30 episodes per hour).

Viz.ai Receives FDA 510(k) Clearance for Artificial Intelligence Algorithm for the Quantification of Intracerebral Hemorrhage

Retrieved on: 
星期四, 二月 8, 2024
Technology, Hospitals, FDA, Health Technology, Cardiology, Software, Practice Management, Health, Data Management, Artificial Intelligence, Radiology, Viz, Neurology, Brain, FRCSC, NCCT, Food, Food and Drug Administration, ICH, AI, University, UTHealth School of Dentistry, MPH, Multimedia, Neurosurgery, Hospital, Stroke, Lateral ventricles, Disease, Intracerebral hemorrhage

“This technology, which marries precision with AI, is poised to transform how we approach intracerebral hemorrhage cases."

Key Points: 
  • “This technology, which marries precision with AI, is poised to transform how we approach intracerebral hemorrhage cases."
  • Intracerebral hemorrhage accounts for up to 15% of all strokes and has high morbidity and mortality rates, demanding swift response.
  • Accurate volume measurements of brain bleeds are crucial for assessing the severity of cases, monitoring progression, and planning treatment strategies.
  • Viz ICH Plus exemplifies our dedication to enhancing patient care by leveraging technology," stated Jayme Strauss, chief clinical officer at Viz.ai.

External Ventricular Drain Market to Record a Growth of USD 2.28 billion between 2023 and 2028, North America to Occupy 35% Market Share - Technavio

Retrieved on: 
星期一, 一月 29, 2024
ROW, Geography, Sleep apnea, Subarachnoid hemorrhage, Gene, Stroke, PD, Birth, Epilepsy, USD, Brain, Chromosome, Traumatic brain injury, DSM-IV codes, EVD, Intracerebral hemorrhage, Ageing, Prevalence, Growth, Pharmaceutical industry

NEW YORK, Jan. 29, 2024 /PRNewswire/ -- The external ventricular drain market is estimated to grow by USD 2.28 billion from 2023 to 2028 at a CAGR of 6.07% according to Technavio.

Key Points: 
  • NEW YORK, Jan. 29, 2024 /PRNewswire/ -- The external ventricular drain market is estimated to grow by USD 2.28 billion from 2023 to 2028 at a CAGR of 6.07% according to Technavio.
  • North America accounts for 35% of the growth of the global market during the forecast period.
  • The external ventricular drain market in North America is poised for rapid expansion, propelled by the increasing prevalence of neurological disorders, the upsurge in the aging population, and advancements in technology.
  • Within this growth trajectory, ischemic strokes stand out as a significant driver of industry progression.

Household Income and Health Insurance Among Factors in Decision to Withdraw Life Support After Hemorrhagic Stroke

Retrieved on: 
星期四, 一月 18, 2024
Koto, Stroke, Death, Roger Hawkins (drummer), Patient, NYU Langone Health, Research, Medicaid, Bleeding, RN, BSN, Health, Intraparenchymal hemorrhage, Medicare, Rehabilitation, Religion, NYU, MSN, Neurosurgery, Coma, Neurology, Blood, Catholic Church, Brain, Intracerebral hemorrhage, Physician, Pharmaceutical industry

Unlike ischemic stroke, which is caused by blocked blood vessels that can be cleared in many cases, hemorrhagic strokes are more often deadly.

Key Points: 
  • Unlike ischemic stroke, which is caused by blocked blood vessels that can be cleared in many cases, hemorrhagic strokes are more often deadly.
  • By contrast, being Black and having private insurance were factors tied to a lower likelihood of life support being withdrawn.
  • Among hospitalized hemorrhagic stroke patients, Blacks made up 7% of those who had life support withdrawn but counted for 18% of those who maintained life support.
  • Similarly, while 37% had private health insurance, only 20% of those who decided to withdraw life support had private insurance.

New VOYAGER PAD Analyses Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin Across High-Risk and Complex Patient Populations with Peripheral Artery Disease (PAD)

Retrieved on: 
星期二, 十一月 14, 2023
ICH, Rivaroxaban, Buerger's test, Research, Safety, Johnson & Johnson, Thrombin, Food, PAD, DPI, American Heart Association, AHA, Risk, Amputation, CAD, Patient, ALI, Myocardial infarction, Intracerebral hemorrhage, Coagulation, LER, TIMI, FDA, Medical Affairs Bureau, Division, Janssen Pharmaceuticals, Comorbidity, MACE, Vascular disease, Stroke, Standard of care, University, Bleeding, Aspirin, EGFR, Janssen, Disability, Anschutz Medical Campus, Metabolism, Pharmaceutical industry

TITUSVILLE, N.J., Nov. 14, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of XARELTO® (rivaroxaban [2.5 mg twice daily plus aspirin 100 mg once daily]) over standard of care (aspirin alone). Data from the two analyses demonstrate the role of XARELTO® in treating both high-risk and fragile patients and those with and without comorbid coronary artery diseases (CAD). Results were presented at the American Heart Association's (AHA) 2023 Scientific Sessions, hosted in Philadelphia, Pennsylvania, November 11-13, 2023.

Key Points: 
  • "These analyses reinforce the consistency of the favorable benefit-risk profile of XARELTO® plus aspirin for patients with vascular disease, regardless of comorbidity.
  • In fragile patients treated with XARELTO® plus aspirin, 6.2% of patients experienced a MALE compared to 10.3% of patients treated with placebo.
  • In patients with PAD only, 11% of patients treated with XARELTO® plus aspirin experienced a MACE versus 9.8% of patients treated with placebo.
  • Overall, the safety of XARELTO® plus aspirin in patients with PAD was consistent regardless of CAD with no significant interactions.

Global Urokinase Market (2023-2028) by Type, Dose Strength, Indication, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis - ResearchAndMarkets.com

Retrieved on: 
星期四, 十一月 9, 2023
Health, Pharmaceutical, Stroke, Allergy, Headache, Incidence, Thrombosis, Vomiting, Laboratory, Prevalence, Face, Myocardial infarction, Pfizer, Clifton Springs Hospital & Clinic, Research, Bleeding, Nausea, Venous thrombosis, Pulmonary embolism, Abbott Laboratories, Fever, Chest pain, Deep vein thrombosis, DVT, Common, Geography, Marketing, Hospital, Atomic mass, Coagulopathy, Merck Group, Wilford Hall Ambulatory Surgical Center, Intracerebral hemorrhage, USD, Blood, Safety, Patient, Cardiovascular disease, COVID-19, Pharmaceutical industry, Birth control

The "Global Urokinase Market (2023-2028) by Type, Dose Strength, Indication, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Urokinase Market (2023-2028) by Type, Dose Strength, Indication, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The urokinase market is being driven by the increasing prevalence of pulmonary embolism (PE), a condition characterized by blood clots in the lungs.
  • Urokinase, a thrombolytic agent, is used to dissolve these clots and is naturally produced by the human body.
  • The urokinase market is highly competitive, featuring numerous players involved in developing and marketing urokinase products.

Lecanemab named one of the world's best inventions in 2023 by TIME

Retrieved on: 
星期二, 十月 24, 2023
Risk, Aneurysm, Vomiting, Cerebral edema, Focal neurologic signs, Incidence, Dementia, Nausea, Disease, Intraparenchymal hemorrhage, Intracerebral hemorrhage, CET, Chills, AI, Paracetamol, Hypersensitivity, Memory, Lecanemab, Vascular malformation, MRI, Excipient, Neuroimaging, Fatal, Thought, Dizziness, Aspirin, Edema, Anticoagulant, Cerebral amyloid angiopathy, Magnetic resonance imaging, Patient, Bronchospasm, Alzheimer's disease, Anaphylaxis, Genetic testing, TIME, ARIA, Arthralgia, Research, Eisai, Fever, Hypotension, Amyloid, Headache, Siderosis, Behavior, Invention, Observation, Hypertension, Confusion, Seizure, Angioedema, Status epilepticus, Tissue plasminogen activator, Pharmaceutical industry, Lace, Medical imaging, Copper

"It is a great honor and tremendous recognition that lecanemab is included in TIME's list of the world's best inventions this year.

Key Points: 
  • "It is a great honor and tremendous recognition that lecanemab is included in TIME's list of the world's best inventions this year.
  • TIME's annual list of the best inventions includes "200 extraordinary innovations changing lives."
  • The information was released for public disclosure, through the agency of the contact persons below, on October 24, 2023, at 4.50 p.m. CET.
  • ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur.

Research in the Special Issue of Journal of Pharmaceutical Analysis Uncovers Previously Unexplored Cellular Mechanisms

Retrieved on: 
星期二, 十月 17, 2023
Male, ICH, Myocardial infarction, IGF1, Stroke, Brain, Intracerebral hemorrhage, UPK3B (gene), JPA, Reactive oxygen species, Toxicity, ECM, Patient, Spatial analysis, PLX3397, Journal, Microglia, Mouse, Extracellular matrix, Dick's Picks Volume 13, Transcriptome, Astrocyte, Prognosis, Inflammation, Research, Medical imaging, Pharmaceutical industry, C3

This comprehensive understanding paves the way for them to uncover some intricate and previously unknown disease mechanisms.

Key Points: 
  • This comprehensive understanding paves the way for them to uncover some intricate and previously unknown disease mechanisms.
  • Three articles in the most recent special issue of the Journal of Pharmaceutical Analysis (JPA) discuss how single-cell and spatially resolved omics help unravel intercellular dynamics, aiding the development of novel therapeutic modalities.
  • The article was available online in February 2023 and published in Volume 13, Issue 8 of JPA in August 2023 .
  • Together, these articles enlighten us with a deeper understanding of cellular mechanisms at the single-cell and spatial levels, offering hope for improved treatment strategies in the future.